Intracystic injection of OK-432: a new sclerosing therapy for cystic hygroma in children.
Nine patients with cystic hygroma were treated with a new sclerosing therapy consisting of intracystic injection of OK-432 (group A Streptococcus pyogenes of human origin). Favourable results including complete regression in eight patients and marked regression in one were observed within 2-3 months without serious side-effects except for fever of 2-3 days' duration and local inflammatory reaction lasting for 3-4 days. Local inflammatory reaction did not cause any damage to the overlying skin and did not lead to scar formation.
D000008:Abdominal Neoplasms / Q000628:therapy; D000293:Adolescent; D001688:Biological Products / Q000008:administration & dosage*; D002675:Child, Preschool; D005260:Female; D006258:Head and Neck Neoplasms / Q000628:therapy; D006801:Humans; D007223:Infant; D008202:Lymphangioma / Q000628:therapy*; D008297:Male; D010844:Picibanil / Q000008:administration & dosage* / Q000627:therapeutic use; D012186:Retroperitoneal Neoplasms / Q000628:therapy; D012597:Sclerosing Solutions / Q000008:administration & dosage* / Q000627:therapeutic use
D001688:Biological Products; D012597:Sclerosing Solutions; D010844:Picibanil